Home LiteratureArticle Details
PMID: 25036462 Published · epublish English Journal Article Research Support, Non-U.S. Gov't Review

Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases.

Viruses ·Vol. 6 ·No. 7 ·2014-07-17 ·Pages 2735-61

Altenburg AF, Kreijtz JH, de Vries RD, Song F, Fux R, Rimmelzwaan GF, Sutter G, Volz A

Abstract

Respiratory viruses infections caused by influenza viruses, human parainfluenza virus (hPIV), respiratory syncytial virus (RSV) and coronaviruses are an eminent threat for public health. Currently, there are no licensed vaccines available for hPIV, RSV and coronaviruses, and the available seasonal influenza vaccines have considerable limitations. With regard to pandemic preparedness, it is important that procedures are in place to respond rapidly and produce tailor made vaccines against these respiratory viruses on short notice. Moreover, especially for influenza there is great need for the development of a universal vaccine that induces broad protective immunity against influenza viruses of various subtypes. Modified Vaccinia Virus Ankara (MVA) is a replication-deficient viral vector that holds great promise as a vaccine platform. MVA can encode one or more foreign antigens and thus functions as a multivalent vaccine. The vector can be used at biosafety level 1, has intrinsic adjuvant capacities and induces humoral and cellular immune responses. However, there are some practical and regulatory issues that need to be addressed in order to develop MVA-based vaccines on short notice at the verge of a pandemic. In this review, we discuss promising novel influenza virus vaccine targets and the use of MVA for vaccine development against various respiratory viruses.

MeSH Terms
Animals Antibodies, Viral/biosynthesis Cross Protection Genetic Vectors Humans Influenza, Human/immunology,prevention & control,virology Orthomyxoviridae/drug effects,immunology,pathogenicity Respiratory Syncytial Viruses/drug effects,immunology,pathogenicity Respiratory Tract Infections/immunology,prevention & control,virology Respirovirus/drug effects,immunology,pathogenicity SARS Virus/drug effects,immunology,pathogenicity Vaccines, Synthetic Vaccinia virus/genetics,immunology Viral Vaccines/administration & dosage,genetics,immunology
Chemicals
Antibodies, Viral Vaccines, Synthetic Viral Vaccines
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Altenburg Arwen F
Department of Viroscience, Erasmus Medical Center (EMC), P.O. Box 2040, 3000 CA Rotterdam, The Netherlands. [email protected].
Kreijtz Joost H C M
Department of Viroscience, Erasmus Medical Center (EMC), P.O. Box 2040, 3000 CA Rotterdam, The Netherlands. [email protected].
de Vries Rory D
Department of Viroscience, Erasmus Medical Center (EMC), P.O. Box 2040, 3000 CA Rotterdam, The Netherlands. [email protected].
Song Fei
Institute for Infectious Diseases and Zoonoses, LMU, University of Munich, 80539, Munich, Germany. [email protected].
Fux Robert
Institute for Infectious Diseases and Zoonoses, LMU, University of Munich, 80539, Munich, Germany. [email protected].
Rimmelzwaan Guus F
Department of Viroscience, Erasmus Medical Center (EMC), P.O. Box 2040, 3000 CA Rotterdam, The Netherlands. [email protected].
Sutter Gerd
Institute for Infectious Diseases and Zoonoses, LMU, University of Munich, 80539, Munich, Germany. [email protected].
Volz Asisa
Institute for Infectious Diseases and Zoonoses, LMU, University of Munich, 80539, Munich, Germany. [email protected].
References (144)
144 references, click to expand
  1. Vectors based on modified vaccinia Ankara expressing influenza H5N1 hemagglutinin induce substantial cross-clade protective immunity.
    PLoS One. 2011 Jan 24;6(1):e16247 PMID: 21283631
  2. Influenza virus hemagglutinin stalk-based antibodies and vaccines.
    Curr Opin Virol. 2013 Oct;3(5):521-30 PMID: 23978327
  3. Guiding the immune response against influenza virus hemagglutinin toward the conserved stalk domain by hyperglycosylation of the globular head domain.
    J Virol. 2014 Jan;88(1):699-704 PMID: 24155380
  4. The immunogenicity and efficacy of intranasally or parenterally administered replication-deficient vaccinia-parainfluenza virus type 3 recombinants in rhesus monkeys.
    Vaccine. 1998 Aug;16(13):1324-30 PMID: 9682397
  5. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line.
    Virology. 1997 Nov 24;238(2):198-211 PMID: 9400593
  6. Vaccination with recombinant modified vaccinia virus Ankara expressing bovine respiratory syncytial virus (bRSV) proteins protects calves against RSV challenge.
    Vaccine. 2007 Jun 15;25(25):4818-27 PMID: 17499893
  7. Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines.
    J Virol. 2006 Dec;80(23):11756-66 PMID: 16971435
  8. New class of monoclonal antibodies against severe influenza: prophylactic and therapeutic efficacy in ferrets.
    PLoS One. 2010 Feb 08;5(2):e9106 PMID: 20161706
  9. Highly attenuated poxviruses induce functional priming of neutrophils in vitro.
    Arch Virol. 1994;136(1-2):219-26 PMID: 8002789
  10. Characterization of the human CD8⁺ T cell response following infection with 2009 pandemic influenza H1N1 virus.
    J Virol. 2011 Nov;85(22):12057-61 PMID: 21917970
  11. Transmission of influenza A/H5N1 viruses in mammals.
    Virus Res. 2013 Dec 5;178(1):15-20 PMID: 23954580
  12. Heterosubtypic antibody recognition of the influenza virus hemagglutinin receptor binding site enhanced by avidity.
    Proc Natl Acad Sci U S A. 2012 Oct 16;109(42):17040-5 PMID: 23027945
  13. Fowlpox virus host range restriction: gene expression, DNA replication, and morphogenesis in nonpermissive mammalian cells.
    Virology. 1993 Nov;197(1):439-44 PMID: 8212580
  14. New avian suspension cell lines provide production of influenza virus and MVA in serum-free media: studies on growth, metabolism and virus propagation.
    Vaccine. 2009 Aug 6;27(36):4975-82 PMID: 19531390
  15. Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus.
    J Gen Virol. 2002 Aug;83(Pt 8):1851-1859 PMID: 12124449
  16. Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans.
    Clin Infect Dis. 2012 Jul;55(1):19-25 PMID: 22441650
  17. Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region.
    J Virol. 2005 Mar;79(5):2678-88 PMID: 15708987
  18. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity.
    J Immunol. 2004 May 1;172(9):5598-605 PMID: 15100303
  19. Interferon induction in peripheral blood mononuclear leukocytes of man and farm animals by poxvirus vector candidates and some poxvirus constructs.
    Vet Immunol Immunopathol. 1995 Jun;46(3-4):237-50 PMID: 7502485
  20. Recombinant viral vectors: cancer vaccines.
    Adv Drug Deliv Rev. 2006 Oct 1;58(8):931-47 PMID: 17030074
  21. Adjuvants and immunization strategies to induce influenza virus hemagglutinin stalk antibodies.
    PLoS One. 2013 Nov 06;8(11):e79194 PMID: 24223176
  22. Limited airborne transmission of H7N9 influenza A virus between ferrets.
    Nature. 2013 Sep 26;501(7468):560-3 PMID: 23925116
  23. Pre-existing immunity against vaccine vectors--friend or foe?
    Microbiology (Reading). 2013 Jan;159(Pt 1):1-11 PMID: 23175507
  24. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans.
    Nat Med. 2012 Jan 29;18(2):274-80 PMID: 22286307
  25. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells.
    PLoS One. 2008;3(12):e3942 PMID: 19079604
  26. Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential?
    Curr Opin Biotechnol. 2004 Dec;15(6):506-12 PMID: 15560976
  27. Human T-cells directed to seasonal influenza A virus cross-react with 2009 pandemic influenza A (H1N1) and swine-origin triple-reassortant H3N2 influenza viruses.
    J Gen Virol. 2013 Mar;94(Pt 3):583-592 PMID: 23152369
  28. MVA vectors expressing conserved influenza proteins protect mice against lethal challenge with H5N1, H9N2 and H7N1 viruses.
    PLoS One. 2014 Feb 11;9(2):e88340 PMID: 24523886
  29. Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies.
    J Virol. 2013 Nov;87(21):11950-4 PMID: 23986586
  30. Towards a universal vaccine for avian influenza: protective efficacy of modified Vaccinia virus Ankara and Adenovirus vaccines expressing conserved influenza antigens in chickens challenged with low pathogenic avian influenza virus.
    Vaccine. 2013 Jan 11;31(4):670-5 PMID: 23200938
  31. Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques.
    J Infect Dis. 2009 Feb 1;199(3):405-13 PMID: 19061423
  32. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells.
    J Gen Virol. 1998 Feb;79 ( Pt 2):347-52 PMID: 9472619
  33. Highly conserved protective epitopes on influenza B viruses.
    Science. 2012 Sep 14;337(6100):1343-8 PMID: 22878502
  34. Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses.
    Vaccine. 2009 Oct 23;27(45):6296-9 PMID: 19840663
  35. Cross-neutralization of influenza A viruses mediated by a single antibody loop.
    Nature. 2012 Sep 27;489(7417):526-32 PMID: 22982990
  36. Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza.
    J Virol. 1996 Sep;70(9):6418-24 PMID: 8709274
  37. Antibody recognition of a highly conserved influenza virus epitope.
    Science. 2009 Apr 10;324(5924):246-51 PMID: 19251591
  38. A pandemic influenza H1N1 live vaccine based on modified vaccinia Ankara is highly immunogenic and protects mice in active and passive immunizations.
    PLoS One. 2010 Aug 16;5(8):e12217 PMID: 20808939
  39. Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years.
    Virus Res. 2011 Dec;162(1-2):80-99 PMID: 21963675
  40. Influenza virus vaccines: lessons from the 2009 H1N1 pandemic.
    Curr Opin Virol. 2011 Oct;1(4):254-62 PMID: 22125588
  41. Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies.
    J Virol. 2000 May;74(9):4236-43 PMID: 10756037
  42. A contributing role for anti-neuraminidase antibodies on immunity to pandemic H1N1 2009 influenza A virus.
    PLoS One. 2011;6(10):e26335 PMID: 22039464
  43. MVA-based H5N1 vaccine affords cross-clade protection in mice against influenza A/H5N1 viruses at low doses and after single immunization.
    PLoS One. 2009 Nov 12;4(11):e7790 PMID: 19915662
  44. Nonreplicating vaccinia vector efficiently expresses recombinant genes.
    Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10847-51 PMID: 1438287
  45. Immunization with recombinant modified vaccinia Ankara (rMVA) constructs encoding the HA or NP gene protects ponies from equine influenza virus challenge.
    Vaccine. 2006 Feb 20;24(8):1180-90 PMID: 16194586
  46. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia.
    N Engl J Med. 2012 Nov 8;367(19):1814-20 PMID: 23075143
  47. A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin.
    J Virol. 2011 Oct;85(20):10905-8 PMID: 21849447
  48. Double-stranded RNA is a trigger for apoptosis in vaccinia virus-infected cells.
    J Virol. 1997 Mar;71(3):1992-2003 PMID: 9032331
  49. Recombinant soluble, multimeric HA and NA exhibit distinctive types of protection against pandemic swine-origin 2009 A(H1N1) influenza virus infection in ferrets.
    J Virol. 2010 Oct;84(19):10366-74 PMID: 20686020
  50. Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions.
    J Virol. 1988 Aug;62(8):2762-72 PMID: 2455818
  51. Identification of a novel coronavirus in patients with severe acute respiratory syndrome.
    N Engl J Med. 2003 May 15;348(20):1967-76 PMID: 12690091
  52. Induced bronchus-associated lymphoid tissue serves as a general priming site for T cells and is maintained by dendritic cells.
    J Exp Med. 2009 Nov 23;206(12):2593-601 PMID: 19917776
  53. Protective efficacy of several vaccines against highly pathogenic H5N1 avian influenza virus under experimental conditions.
    Vaccine. 2008 Mar 20;26(13):1688-96 PMID: 18291561
  54. Modified vaccinia virus Ankara expressing the hemagglutinin of pandemic (H1N1) 2009 virus induces cross-protective immunity against Eurasian 'avian-like' H1N1 swine viruses in mice.
    Influenza Other Respir Viruses. 2014 May;8(3):367-75 PMID: 24373385
  55. Poxvirus vectors.
    Vaccine. 2013 Sep 6;31(39):4217-9 PMID: 23834812
  56. [MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl)].
    Dtsch Med Wochenschr. 1974 Nov 22;99(47):2386-92 PMID: 4426258
  57. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses.
    Nat Struct Mol Biol. 2009 Mar;16(3):265-73 PMID: 19234466
  58. IL-17-induced CXCL12 recruits B cells and induces follicle formation in BALT in the absence of differentiated FDCs.
    J Exp Med. 2014 Apr 7;211(4):643-51 PMID: 24663215
  59. Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome.
    PLoS Pathog. 2009 Jun;5(6):e1000480 PMID: 19543380
  60. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine.
    J Gen Virol. 1998 May;79 ( Pt 5):1159-67 PMID: 9603331
  61. Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses.
    J Virol. 2013 Oct;87(19):10435-46 PMID: 23903831
  62. Memory CD4 T cells direct protective responses to influenza virus in the lungs through helper-independent mechanisms.
    J Virol. 2010 Sep;84(18):9217-26 PMID: 20592069
  63. Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza A virus.
    J Virol. 2008 Jun;82(11):5161-6 PMID: 18353950
  64. Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1.
    Clin Infect Dis. 2011 Jan 1;52(1):1-7 PMID: 21148512
  65. Vaccination of infant macaques with a recombinant modified vaccinia virus Ankara expressing the respiratory syncytial virus F and G genes does not predispose for immunopathology.
    Vaccine. 2004 Feb 25;22(8):923-6 PMID: 15161069
  66. Modified vaccinia virus Ankara induces Toll-like receptor-independent type I interferon responses.
    J Virol. 2007 Nov;81(22):12102-10 PMID: 17855554
  67. Modified vaccinia virus ankara triggers chemotaxis of monocytes and early respiratory immigration of leukocytes by induction of CCL2 expression.
    J Virol. 2009 Mar;83(6):2540-52 PMID: 19129447
  68. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans.
    PLoS Med. 2007 Feb;4(2):e59 PMID: 17298168
  69. Evaluation of a modified vaccinia virus Ankara (MVA)-based candidate pandemic influenza A/H1N1 vaccine in the ferret model.
    J Gen Virol. 2010 Nov;91(Pt 11):2745-52 PMID: 20719991
  70. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection.
    J Immunol. 2011 Jan 15;186(2):1022-31 PMID: 21169548
  71. Human monoclonal antibodies to pandemic 1957 H2N2 and pandemic 1968 H3N2 influenza viruses.
    J Virol. 2012 Jun;86(11):6334-40 PMID: 22457520
  72. Induction of virus-specific cytotoxic T lymphocytes as a basis for the development of broadly protective influenza vaccines.
    J Biomed Biotechnol. 2011;2011:939860 PMID: 22007149
  73. RSV 2010: Recent advances in research on respiratory syncytial virus and other pneumoviruses.
    Vaccine. 2011 Oct 6;29(43):7285-91 PMID: 21827813
  74. Cellular immune correlates of protection against symptomatic pandemic influenza.
    Nat Med. 2013 Oct;19(10):1305-12 PMID: 24056771
  75. Infection with seasonal influenza virus elicits CD4 T cells specific for genetically conserved epitopes that can be rapidly mobilized for protective immunity to pandemic H1N1 influenza virus.
    J Virol. 2011 Dec;85(24):13310-21 PMID: 21976658
  76. DNA and modified vaccinia virus Ankara vaccines encoding multiple cytotoxic and helper T-lymphocyte epitopes of human immunodeficiency virus type 1 (HIV-1) are safe but weakly immunogenic in HIV-1-uninfected, vaccinia virus-naive adults.
    Clin Vaccine Immunol. 2012 May;19(5):649-58 PMID: 22398243
  77. Airborne transmission of influenza A/H5N1 virus between ferrets.
    Science. 2012 Jun 22;336(6088):1534-41 PMID: 22723413
  78. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins.
    Science. 2011 Aug 12;333(6044):850-6 PMID: 21798894
  79. Protective and disease-enhancing immune responses induced by recombinant modified vaccinia Ankara (MVA) expressing respiratory syncytial virus proteins.
    Vaccine. 2004 Nov 25;23(2):215-21 PMID: 15531040
  80. Introduction of the six major genomic deletions of modified vaccinia virus Ankara (MVA) into the parental vaccinia virus is not sufficient to reproduce an MVA-like phenotype in cell culture and in mice.
    J Virol. 2010 Oct;84(19):9907-19 PMID: 20668072
  81. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis.
    Lancet Infect Dis. 2012 Jan;12(1):36-44 PMID: 22032844
  82. Cytotoxic T-cell immunity to influenza.
    N Engl J Med. 1983 Jul 7;309(1):13-7 PMID: 6602294
  83. Pathways of antigen processing.
    Annu Rev Immunol. 2013;31:443-73 PMID: 23298205
  84. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence.
    J Gen Virol. 1991 May;72 ( Pt 5):1031-8 PMID: 2033387
  85. Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model.
    Vaccine. 1997 Mar;15(4):387-94 PMID: 9141209
  86. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus.
    Vaccine. 1994 Aug;12(11):1032-40 PMID: 7975844
  87. Clearance of influenza virus infections by T cells: risk of collateral damage?
    Curr Opin Virol. 2013 Aug;3(4):430-7 PMID: 23721864
  88. A decade after SARS: strategies for controlling emerging coronaviruses.
    Nat Rev Microbiol. 2013 Dec;11(12):836-48 PMID: 24217413
  89. A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years.
    PLoS One. 2012;7(10):e48322 PMID: 23118984
  90. H3 stalk-based chimeric hemagglutinin influenza virus constructs protect mice from H7N9 challenge.
    J Virol. 2014 Feb;88(4):2340-3 PMID: 24307585
  91. [Changes in the vaccinia virus through continuing passages in chick embryo fibroblast cultures].
    Zentralbl Bakteriol Orig. 1964 Dec;195(1):24-35 PMID: 5890664
  92. Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies.
    Proc Natl Acad Sci U S A. 2008 Apr 22;105(16):5986-91 PMID: 18413603
  93. Improved adjuvanting of seasonal influenza vaccines: preclinical studies of MVA-NP+M1 coadministration with inactivated influenza vaccine.
    Eur J Immunol. 2013 Jul;43(7):1940-52 PMID: 23589155
  94. Pathogenesis of acute respiratory illness caused by human parainfluenza viruses.
    Curr Opin Virol. 2012 Jun;2(3):294-9 PMID: 22709516
  95. Memory CD4+ T cells protect against influenza through multiple synergizing mechanisms.
    J Clin Invest. 2012 Aug;122(8):2847-56 PMID: 22820287
  96. Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children.
    Clin Vaccine Immunol. 2008 Jul;15(7):1042-53 PMID: 18448618
  97. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine.
    J Clin Invest. 2010 May;120(5):1663-73 PMID: 20389023
  98. Bovine model of respiratory syncytial virus infection.
    Curr Top Microbiol Immunol. 2013;372:327-45 PMID: 24362697
  99. A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains.
    J Virol. 1993 May;67(5):2552-8 PMID: 7682624
  100. Immunity against heterosubtypic influenza virus induced by adenovirus and MVA expressing nucleoprotein and matrix protein-1.
    Sci Rep. 2013;3:1443 PMID: 23485942
  101. Protection from the 2009 H1N1 pandemic influenza by an antibody from combinatorial survivor-based libraries.
    PLoS Pathog. 2010 Jul 08;6(7):e1000990 PMID: 20628565
  102. Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice.
    Vaccine. 2007 Jan 8;25(4):612-20 PMID: 17005299
  103. Assessment of influenza virus hemagglutinin stalk-based immunity in ferrets.
    J Virol. 2014 Mar;88(6):3432-42 PMID: 24403585
  104. Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model.
    Vaccine. 1996 Oct;14(15):1451-8 PMID: 8994321
  105. Influenza viruses expressing chimeric hemagglutinins: globular head and stalk domains derived from different subtypes.
    J Virol. 2012 May;86(10):5774-81 PMID: 22398287
  106. Inactivated seasonal influenza vaccines increase serum antibodies to the neuraminidase of pandemic influenza A(H1N1) 2009 virus in an age-dependent manner.
    J Infect Dis. 2010 Dec 1;202(11):1634-8 PMID: 20979454
  107. Comparison of the immunogenicity and efficacy of a replication-defective vaccinia virus expressing antigens of human parainfluenza virus type 3 (HPIV3) with those of a live attenuated HPIV3 vaccine candidate in rhesus monkeys passively immunized with PIV3 antibodies.
    J Infect Dis. 1999 Jun;179(6):1345-51 PMID: 10228053
  108. Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults.
    Vaccine. 2011 Jul 18;29(32):5145-52 PMID: 21624416
  109. Cross-priming of cytotoxic T cells dictates antigen requisites for modified vaccinia virus Ankara vector vaccines.
    J Virol. 2007 Nov;81(21):11925-36 PMID: 17699574
  110. Human cytotoxic T lymphocytes directed to seasonal influenza A viruses cross-react with the newly emerging H7N9 virus.
    J Virol. 2014 Feb;88(3):1684-93 PMID: 24257602
  111. Development of universal influenza vaccines based on influenza virus M and NP genes.
    Infection. 2014 Apr;42(2):251-62 PMID: 24178189
  112. Global production capacity of seasonal influenza vaccine in 2011.
    Vaccine. 2013 Jan 21;31(5):728-31 PMID: 23149268
  113. A common solution to group 2 influenza virus neutralization.
    Proc Natl Acad Sci U S A. 2014 Jan 7;111(1):445-50 PMID: 24335589
  114. Recommended composition of influenza virus vaccines for use in the 2014-2015 northern hemisphere influenza season.
    Wkly Epidemiol Rec. 2014 Mar 7;89(10):93-104 PMID: 24707514
  115. Stable antigen is most effective for eliciting CD8+ T-cell responses after DNA vaccination and infection with recombinant vaccinia virus in vivo.
    J Virol. 2012 Sep;86(18):9782-93 PMID: 22761378
  116. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice.
    Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6641-6 PMID: 15096611
  117. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses.
    Virology. 1998 May 10;244(2):365-96 PMID: 9601507
  118. H3N2 influenza virus infection induces broadly reactive hemagglutinin stalk antibodies in humans and mice.
    J Virol. 2013 Apr;87(8):4728-37 PMID: 23408625
  119. Multiple heterologous M2 extracellular domains presented on virus-like particles confer broader and stronger M2 immunity than live influenza A virus infection.
    Antiviral Res. 2013 Sep;99(3):328-35 PMID: 23811283
  120. Influenza virus-like particles containing M2 induce broadly cross protective immunity.
    PLoS One. 2011 Jan 18;6(1):e14538 PMID: 21267073
  121. A universal influenza A vaccine based on the extracellular domain of the M2 protein.
    Nat Med. 1999 Oct;5(10):1157-63 PMID: 10502819
  122. Characterization of immunity induced by M2e of influenza virus.
    Vaccine. 2007 Dec 17;25(52):8868-73 PMID: 18061317
  123. Studies on poxvirus infections in irradiated animals.
    Arch Virol. 1980;64(3):247-56 PMID: 6250514
  124. Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1.
    J Infect Dis. 2007 Jun 1;195(11):1598-606 PMID: 17471429
  125. [The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)].
    Zentralbl Bakteriol B. 1978 Dec;167(5-6):375-90 PMID: 219640
  126. Identification of viral molecules recognized by influenza-specific human cytotoxic T lymphocytes.
    J Exp Med. 1987 Feb 1;165(2):408-16 PMID: 3029268
  127. Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes.
    Proc Natl Acad Sci U S A. 1985 Mar;82(6):1785-9 PMID: 3872457
  128. Clinical applications of attenuated MVA poxvirus strain.
    Expert Rev Vaccines. 2013 Dec;12(12):1395-416 PMID: 24168097
  129. Recognition of influenza A virus nucleoprotein by human cytotoxic T lymphocytes.
    J Gen Virol. 1986 Apr;67 ( Pt 4):719-26 PMID: 3485697
  130. Human CD8+ and CD4+ T lymphocyte memory to influenza A viruses of swine and avian species.
    J Immunol. 1999 Jun 15;162(12):7578-83 PMID: 10358215
  131. Highly attenuated poxvirus vectors.
    AIDS Res Hum Retroviruses. 1992 Aug;8(8):1445-7 PMID: 1466978
  132. CD4 T cell-mediated protection from lethal influenza: perforin and antibody-mediated mechanisms give a one-two punch.
    J Immunol. 2006 Sep 1;177(5):2888-98 PMID: 16920924
  133. Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses.
    Mol Ther. 2014 Jan;22(1):233-8 PMID: 23831594
  134. Examination of influenza specific T cell responses after influenza virus challenge in individuals vaccinated with MVA-NP+M1 vaccine.
    PLoS One. 2013 May 03;8(5):e62778 PMID: 23658773
  135. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara.
    J Virol. 1996 Jun;70(6):3741-52 PMID: 8648709
  136. Easy and efficient protocols for working with recombinant vaccinia virus MVA.
    Methods Mol Biol. 2012;890:59-92 PMID: 22688761
  137. Clinical development of Modified Vaccinia virus Ankara vaccines.
    Vaccine. 2013 Sep 6;31(39):4241-6 PMID: 23523410
  138. Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA.
    Vaccine. 1999 Oct 14;18(5-6):392-7 PMID: 10519927
  139. Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines.
    Rev Med Virol. 2012 Jul;22(4):267-79 PMID: 22438243
  140. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1.
    Emerg Infect Dis. 2007 Mar;13(3):426-35 PMID: 17552096
  141. Cross-protection against a lethal influenza virus infection by DNA vaccine to neuraminidase.
    Vaccine. 2000 Aug 1;18(28):3214-22 PMID: 10869766
  142. Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments.
    Expert Rev Vaccines. 2009 Apr;8(4):499-508 PMID: 19348565
  143. Cross-protective immunity against multiple influenza virus subtypes by a novel modified vaccinia Ankara (MVA) vectored vaccine in mice.
    Vaccine. 2013 Apr 3;31(14):1848-55 PMID: 23376279
  144. Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine.
    J Virol. 2000 Jan;74(2):923-33 PMID: 10623755
Article Info
Journal
Viruses
Abbr.
Viruses
ISSN
1999-4915
DOI
10.3390/v6072735
Email
[email protected]
[email protected]
[email protected]
[email protected]
[email protected]
[email protected]
[email protected]
[email protected]
Published
2014-07-17
Epub
2014-00-17
Pages
2735-61
Language
English
Region
Switzerland
NLM ID
101509722
PMCID
PMC4113791
Subset
IM
External Links
PubMed source DOI: 10.3390/v6072735 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2